Henry, K <br/><br/>
Twice-daily triple nucleoside intensification treatment with lamivudine-zidovudine plus abacavir sustains suppression of human immunodeficiency virus type 1: results of the TARGET Study.  [electronic resource] 

 -  The Journal of infectious diseases  Feb 2001 
 - 571-8 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Multicenter Study 
<br/><br/><label>ISSN: </label>0022-1899 
<br/><br/><label>Standard No.: </label>10.1086/318527  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Anti-HIV Agents--administration & dosage<br/>CD4 Lymphocyte Count<br/>Dideoxynucleosides--administration & dosage<br/>Drug Therapy, Combination<br/>Female<br/>HIV Infections--drug therapy<br/>HIV-1--genetics<br/>Humans<br/>Lamivudine--administration & dosage<br/>Male<br/>Middle Aged<br/>RNA, Viral--blood<br/>Reverse Transcriptase Inhibitors--therapeutic use<br/>Treatment Outcome<br/>Viral Load<br/>Zidovudine--administration & dosage